Transcript Planned achievements: new tools

The Research and
Development Goals
of
the Global Plan
to Stop TB 2006-2015
Marcos Espinal
Executive Secretary
THE STOP TB PARTNERSHIP
Targets
By 2015: the global burden of TB
disease (deaths and prevalence)
will be reduced by 50% relative to
1990 levels.
By 2050: The global incidence of
TB disease will be less than 1 per
million population.
Our vision is a TB-free world:
The first children born this
millennium will see TB
eliminated in their lifetime.
Stop TB is a global movement
to accelerate social and
political action to stop the
unnecessary spread of TB
around the world.
EXPECTED RESULTS OF THE GLOBAL PLAN
- Achieve the Millennium Development Goal to have halted and begun to
reverse the incidence of TB by 2015
- Save an additional 14 million lives
- Treat 50 million people for TB
- Put 3 million TB patients coinfected with HIV on ARVs
- Treat 800,000 people for MDR-TB
- Expand access to high-quality TB diagnosis and treatment for all
- Produce the first new anti-TB drug in 40 years by 2010
- Develop a new vaccine by 2015
- Provide rapid and inexpensive diagnostic tests at the point of care
Major planned achievements
New Tools Working Groups
- by 2006: Introduction of the 1st new diagnostic for culture and sensitivity
testing
- by 2010: New rapid diagnostic at clinic level
- by 2010: New drugs will be launched
- by 2015: New regimen of novel chemical entities (treatment shortened)
- by 2015: New generation of vaccines
New TB Vaccines Working Group strategic vision
Aim: bring together the wide range of international groups with an interest in TB
vaccine development, acting as a "broker" to promote synergy and to
accelerate identification and introduction of the most effective vaccination
strategy.
1.
Coordinate international activities that strengthen and accelerate the development and introduction
of improved TB vaccines
2.
Promote a concerted approach to development and introduction of improved TB vaccines by
encouraging useful interactions among different groups
3.
Prioritize actions needed and areas of new resources, including epidemiological studies, costeffectiveness studies, formation of public/private partnerships for vaccine production, programs to
address issues of regulatory streamlining and technology transfer that will advance the sustained
access of improved TB vaccines to endemic countries
4.
Formulate with other Stop TB partners and Working Groups the integration of vaccine,
immunotherapy and drug treatment programs to eliminate TB
New TB Vaccines Working Group
Main achievements as of December 2007
- KEEP THE VACCINES PIPELINE FILLED
• Priming, pre-exposure : 10 candidates (Phase I in 2008, 2009 or later)
• Boosting, pre-exposure: 17 candidates (Phase I in 2008, 2009 or later)
• Post exposure, immunotherapy: 12 candidates (Phase I in 2008, 2009 or later)
– MAINTAIN AND IMPROVE BCG VACCINES
• Development of a plan for vaccine production capacity and scale-up (AERAS)
– CAPACITY AT NEW TB VACCINES TRIAL SITES
• Phase III trial sites has been expanded beyond South-Africa to Ethiopia, India
and Uganda (AERAS, EU Country Clinical Trials Platform & EU TBVAC initiatives)
New TB Diagnostics Working Group
Strategic vision
Aim: a group of Partners working to introduce cost-effective and appropriate new
diagnostic tools that will contribute towards control of global TB epidemic and
improve quality of patient care.
The ideal toolbox will contain a portfolio of diagnostic technologies that will perform well
in different categories of patients to
1. Improve TB case detection
2. Rapidly identify drug resistant TB
3. Reliable identify latent infection and determine risk of progression
Targets for introduction of tests, leading to sustainable
adoption, 2006–2015
New TB Diagnostics Working Group
Main achievements as of December 2007
- EXPANDED DIAGNOSTICS PIPELINE
• WHO STAG recommendation on liquid culture and DST in 2007 (Ref lab level)
• Expert Committee to review evidence on the use of molecular test for rapid
screening of patients at risk of multi-drug resistant TB in 2008 (STAG)
• 10 products at reference lab level (incl liquid culture and speciation test)
• 7 products at peripheral level (incl LED)
• 2 products at point of care
– DEVELOPMENT OF SCIENTIFIC BLUEPRINT
• Development of a roadmap, for best practices guidelines for diagnostic test
development, evaluation and implementation
Main challenges
• Insufficient basic research (TBRM)
• Insufficient funding for TB R&D
– Global funding for TB tools: $413 million
– Funding Gap: $6 billion over the next 10 years
– Investment in TB research was 19 times less than
HIV*
• Inadequate clinical trial platform
• No clear regulatory framework for diagnostics
and TB drugs
• Political awareness
• Sustained political commitment
*Tuberculosis R&D: a critical analysis of funding trends 2005-2006 (Treatment Action Group Report